BIOMERE

About BIOMERE

BIOMERE, initially founded as Biomedical Research Models, Inc. in 1996 by Dennis Guberski, operates as a preclinical contract research organization (CRO). The company is strategically headquartered in Worcester, Massachusetts, placing it in proximity to a major life sciences hub. In December 2019, BIOMERE merged with JOINN Laboratories, the largest non-clinical CRO in China, a move that significantly expanded its global reach and service portfolio. This merger was spearheaded by CEO Mark Nedelman, who joined in 2015 and was instrumental in the company's transformation and growth, which led to the acquisition by JOINN. Following the merger, the company initiated a bi-coastal expansion in the U.S., adding a facility in the San Francisco Bay Area to its operations.

The company provides an extensive portfolio of preclinical research services to drug development companies, assisting them in advancing life science research. Its business model centers on offering specialized, discovery-based services that are not always readily available elsewhere in the industry. BIOMERE serves a client base that ranges from biotechnology and pharmaceutical firms to academic institutions and computational drug discovery labs. Revenue is generated by providing these contract research services, which cover the entire process from early discovery to IND-enabling programs.

BIOMERE's core services include preclinical efficacy, pharmacokinetics (PK/PD), and ADME studies in a variety of animal models, including rodents and non-human primates. The organization has particular expertise in developing animal models for diseases such as Type 1 and Type 2 diabetes and rheumatoid arthritis. Other specialized services encompass surgical procedures, ocular research, oncology, neurology, and studies related to autoimmune and metabolic disorders. A key differentiator is its customer-focused approach, which emphasizes seamless communication and customized study designs to meet specific client needs. Through its integration with JOINN, BIOMERE offers clients the option to conduct GLP-toxicology programs in China, which can reduce time and costs. The company holds multiple accreditations and registrations, including from AAALAC, OLAW, the DEA, and the USDA.